- The Genomics of Gene Regulation (GGR) program, under the NIH umbrella, is getting off the ground with $28 million in government grants that will help scientists gain insight into how genes are turned on and off and other gene expression-related factors.
- Researchers will be studying networks and pathways in different systems of the body, such as the skin, lungs, and immune system.
- Faulty gene regulation is a common underlying factor for diseases such as cancer, diabetes, and neurologic diseases.
Insight into gene regulation is a topic that has long concerned scientists around the U.S. and the world. The funding injection into this research area will undoubtedly contribute to additional knowledge that will drive drug discovery.
Institutions that have received funding through the GGR program so far this year include Memorial Sloan Kettering Cancer Center, Duke University, University of Massachusetts Medical School, Stanford University, and UCLA.
One recipient, Dr. Michael Snyder and his team at Stanford, spoke to BioPharma Dive last year about the exciting potential of genomics and personalized medicine in therapeutic areas such as cancer.